Kamidono S, Fujii A, Harada M, Arakawa S, Umezu K, Kataoka N, Ishigami J, Hirooka K, Shimatani N, Matsushita M
Jpn J Antibiot. 1985 Mar;38(3):869-904.
Fundamental and clinical studies on S6472, a new prolonged acting preparation of cefaclor, were performed and the following results were obtained. Serum level and urinary excretion. 750 mg of S6472, 500 mg of cefaclor (CCL) and 500 mg of cephalexin (CEX) were orally administered in 6 healthy adult volunteers by the cross over method to measure serum level and urinary excretion. The serum level-time curve of S6472 showed 2 peaks at 1 and 6 hours after administration. The peak serum level of S6472 was 4.2 micrograms/ml and 2.9 micrograms/ml, respectively, 1 and 6 hours after administration. The peak serum level of CCL and CEX was 5.8 micrograms/ml and 12.1 micrograms/ml, respectively, 2 hours after administration. The urine level-time curve of S6472 also showed 2 peaks at 0-2 and 4-6 hours after administration and the peak urine level was 1,320 micrograms/ml and 994 micrograms/ml, respectively, 0-2 and 4-6 hours after administration. The peak urine level of CCL was 1,337 micrograms/ml, 0-2 hours after administration and that of CEX was 2,079 micrograms/ml, 2-4 hours. The mean urinary excretion of S6472, CCL and CEX was 56%, 69% and 94% of dose at 12 hours after administration. Clinical evaluation. S6472 was tried in 200 cases of various urinary tract infections. For one group of 85 cases with acute uncomplicated cystitis, clinical effects were evaluated as excellent in 40 cases, moderate in 42 cases and poor in 3 cases, and the overall clinical effectiveness rate was 96.5%. For another group of 68 cases with complicated urinary tract infection, clinical effects were evaluated as excellent in 9 cases, moderate in 27 cases and poor in 32 cases, and the overall clinical effectiveness rate was 52.9%. Side effects. Side effects were observed in 7 cases with diarrhea, epigastralgia, stomatitis, eruption and facial swelling. Administration of S6472 was discontinued in 2 cases, but in 7 cases all symptoms were transient.
对新型长效头孢克洛制剂S6472进行了基础和临床研究,获得了以下结果。血清水平和尿排泄情况:采用交叉法对6名健康成年志愿者口服750毫克S6472、500毫克头孢克洛(CCL)和500毫克头孢氨苄(CEX),以测定血清水平和尿排泄情况。S6472的血清水平-时间曲线在给药后1小时和6小时出现2个峰值。给药后1小时和6小时,S6472的血清峰值水平分别为4.2微克/毫升和2.9微克/毫升。CCL和CEX的血清峰值水平在给药后2小时分别为5.8微克/毫升和12.1微克/毫升。S6472的尿水平-时间曲线在给药后0 - 2小时和4 - 6小时也出现2个峰值,给药后0 - 2小时和4 - 6小时的尿峰值水平分别为1320微克/毫升和994微克/毫升。CCL给药后0 - 2小时的尿峰值水平为1337微克/毫升,CEX给药后2 - 4小时的尿峰值水平为2079微克/毫升。给药后12小时,S6472、CCL和CEX的平均尿排泄量分别为给药剂量的56%、69%和94%。临床评估:对200例各种尿路感染患者试用了S6472。对于一组85例急性单纯性膀胱炎患者,临床疗效评估为优40例,中42例,差3例,总体临床有效率为96.5%。对于另一组68例复杂性尿路感染患者,临床疗效评估为优9例,中27例,差32例,总体临床有效率为52.9%。副作用:观察到7例出现腹泻、上腹部疼痛、口腔炎、皮疹和面部肿胀等副作用。2例停用了S6472,但7例所有症状均为一过性。